Piramal Pharma (NSE:PPLPHARMA) Forward Dividend Yield %: 0.08% (As of Jul. 04, 2026)


NSE:PPLPHARMA Piramal Pharma Ltd NSE:PPLPHARMA
53 GF Score
Price ₹175.95
GF Value ₹176.12
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Piramal Pharma Forward Dividend Yield %?

Piramal Pharma NSE:PPLPHARMA +4.55% 53 Forward Dividend Yield % is 0.08% as of Jul. 04, 2026. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 53/100 and a GF Value™ of ₹176.12 (Fairly Valued). The stock has 3 warning signs investors should review. Among 506 Drug Manufacturers companies, Piramal Pharma ranks worse than 98.22% on this metric.

As of today (2026-07-04), the Forward Annual Dividend Yield of Piramal Pharma is 0.08%.

As of today (2026-07-04), the Trailing Annual Dividend Yield of Piramal Pharma is 0.08%.

NSE:PPLPHARMA's Forward Dividend Yield % is ranked worse than
98.22% of 506 companies
in the Drug Manufacturers industry
Industry Median: 2.03 vs NSE:PPLPHARMA: 0.08

Piramal Pharma's Dividends per Share for the three months ended in Mar. 2026 was ₹0.00.

During the past 12 months, Piramal Pharma's average Dividends Per Share Growth Rate was 27.30% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Piramal Pharma  (NSE:PPLPHARMA) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Piramal Pharma Forward Dividend Yield % Related Terms


NSE:PPLPHARMA vs ZTS, UTHR: Forward Dividend Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Piramal Pharma Forward Dividend Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Piramal Pharma's Forward Dividend Yield % falls into.


NSE:PPLPHARMA
53GF Score
Piramal Pharma Ltd NSE:PPLPHARMA
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Piramal Pharma Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Piramal Pharma Recent Full-Year* Dividend History

Amount Ex-date Record Date Pay Date Type Frequency Forex Rate
INR 0.1400002025-07-162025-07-162025-07-30Cash DividendannuallyINR:INR 1.000000

* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.

Piramal Pharma's Forward Annual Dividend Yield (%) for Today is calculated as

Forward Annual Dividend Yield=Forward Full Year Dividend/Current Share Price
=0.14/175.95
=0.08 %

Current Share Price is ₹175.95.
Piramal Pharma's Dividends per Share for the forward twelve months is calculated as ₹0.14 * 1 = ₹0.14.

Piramal Pharma's Trailing Annual Dividend Yield (%) for Today is calculated as

Trailing Annual Dividend Yield=Most Recent Full Year Dividend/Current Share Price
=0.14/175.95
=0.08 %

Current Share Price is ₹175.95.
Piramal Pharma's Dividends per Share for the trailing twelve months (TTM) ended in Today is ₹0.14.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Forward Dividend Yield % of 0.08% mean?
Piramal Pharma (NSE:PPLPHARMA) has a Forward Dividend Yield % of 0.08% as of Jul. 04, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Piramal Pharma and its competitors. According to the industry distribution chart, Piramal Pharma ranks #497 out of 506 companies in the Drug Manufacturers industry, placing it in the top 98.2%.
Is Piramal Pharma's Forward Dividend Yield % too high?
Piramal Pharma's current Forward Dividend Yield % is 0.08%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.03. Piramal Pharma's value of 0.08% is 96.1% below this industry median. Based on the distribution chart, Piramal Pharma ranks #497 out of 506 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Piramal Pharma has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #497 out of 506 companies for Forward Dividend Yield %. This places Piramal Pharma in the lower half of its industry. The industry median Forward Dividend Yield % is 2.03. Piramal Pharma's value of 0.08% is 96.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.03, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Piramal Pharma's current Forward Dividend Yield % of 0.08% is 96.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Piramal Pharma and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current Forward Dividend Yield % is 0.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹176.12, compared to a current price of ₹175.95 — trading 0.1% below its estimated fair value. The current Forward Dividend Yield % is 0.08% and 96.1% below the Drug Manufacturers industry median of 2.03. Piramal Pharma's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current Forward Dividend Yield % is 0.08% as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Piramal Pharma stock appears to be undervalued. The current stock price of ₹175.95 is trading 0.1% below its estimated GF Value™ of ₹176.12. GuruFocus considers Piramal Pharma to be Fairly Valued.

Key valuation signals for NSE:PPLPHARMA:

  • Forward Dividend Yield %: 0.08%
  • GF Value™: ₹176.12 vs. price of ₹175.95 (0.1% below fair value)
  • GF Score™: 53/100 with 3 warning signs
  • Industry Position: 96.1% below the Drug Manufacturers median (#497 of 506)

No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Piramal Pharma Business Description

Other Exchanges 543635:India
Address Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
53GF Score

Get the complete analysis for NSE:PPLPHARMA

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹175.95
Price
₹176.12
GF Value